Comparative Pharmacology
Head-to-head clinical analysis: SULLA versus SULMEPRIM PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULLA versus SULMEPRIM PEDIATRIC.
SULLA vs SULMEPRIM PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits bacterial dihydrofolate reductase, blocking folate reduction; sequential blockade leads to bactericidal effect.
100 mg orally once daily, increased to 200 mg daily if needed.
For Pneumocystis jirovecii pneumonia (PCP): 15-20 mg/kg/day (based on trimethoprim component) intravenously divided every 6-8 hours for 14-21 days. For other infections: 8-10 mg/kg/day (trimethoprim) orally or intravenously divided every 12 hours.
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life: Sulfamethoxazole 9–12 hours, Trimethoprim 8–11 hours; prolonged in renal impairment (creatinine clearance <15 mL/min) requiring dose adjustment.
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Renal excretion accounts for approximately 70% (as unchanged sulfamethoxazole and trimethoprim) and 20% as metabolites; biliary/fecal elimination is minor at <10%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic